10-QPeriod: Q3 FY2018

CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2018

Filed November 6, 2018For Securities:CVS

Summary

CVS Health Corporation's (CVS) 10-Q filing for the period ending September 29, 2018, reveals key financial performance and operational highlights. The company is navigating a period of significant transition, likely influenced by its pending acquisition of Aetna. Investors should pay close attention to revenue trends across its segments, particularly the Pharmacy Services and Retail/Long-Term Care divisions, as these are critical drivers of the company's overall financial health. Management's discussion on liquidity and capital resources will be crucial for understanding the company's ability to fund ongoing operations and strategic initiatives. While specific financial figures for the quarter are not detailed in the provided excerpt, the filing indicates a focus on the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section. This section will offer insights into the factors affecting the company's performance, including any impacts from integration activities related to the Aetna deal. Investors should also review the "Legal Proceedings" for any potential material risks and the "Controls and Procedures" for assurances on financial reporting integrity.

Financial Highlights

58 data points
Beta

Revenue

$47.49B

15.4% Gross Margin

Net Income

$1.39B

2.9% Net Margin

EPS (Diluted)

$1.36

Total Assets

$131.51B

Cash & Equivalents

$41.59B

Free Cash Flow

$557.00M

Financial Statements
Beta
Revenue$47.49B
Cost of Revenue$39.50B
Gross Profit$7.33B
Operating Expenses$44.92B
Operating Income$2.57B
Interest Expense$674.00M
Net Income$1.39B
EPS (Basic)$1.36
EPS (Diluted)$1.36
Shares Outstanding (Basic)1.02B
Shares Outstanding (Diluted)1.02B

Key Highlights

  • 1The filing covers the unaudited condensed consolidated financial statements for the three and nine months ended September 29, 2018, compared to the prior year periods.
  • 2Key financial statements include the Statement of Operations, Comprehensive Income, Balance Sheets, and Cash Flows.
  • 3Management's Discussion and Analysis (MD&A) of Financial Condition and Results of Operations is a critical section for understanding performance drivers and future outlook.
  • 4The company is likely undergoing significant strategic initiatives, potentially including the integration of a major acquisition (Aetna).
  • 5Investors should review legal proceedings for any potential risks that could impact financial performance.
  • 6Disclosure on controls and procedures is included to provide assurance on the reliability of financial reporting.
  • 7The balance sheet as of September 30, 2018, and December 31, 2017, will provide insights into the company's asset and liability structure.

Frequently Asked Questions

The provided excerpt does not contain specific revenue figures for the quarter. Investors should refer to the "Condensed Consolidated Statements of Operations" and the "Management's Discussion and Analysis" sections within the full 10-Q filing for a detailed breakdown of revenue by segment and the factors influencing performance.

While the excerpt mentions the filing date and standard financial statements, it doesn't detail the specific impact of the Aetna acquisition. The "Management's Discussion and Analysis" section is the most likely place to find information on how the integration is progressing, any associated costs, and its effect on liquidity and strategic outlook.

The filing includes a "Condensed Consolidated Statements of Cash Flows" for the nine months ended September 30, 2018. Investors should examine this statement to understand the company's cash generation from operations, investing activities, and financing activities. The "Management's Discussion and Analysis" will provide further qualitative insights into liquidity and capital resources.

Item 1 of Part II in the filing addresses "Legal Proceedings." Investors should review this section of the full 10-Q report to identify any pending litigation or regulatory matters that could pose a material risk to the company's financial health or operations.